Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.

Busner, Joan; Pandina, Gahan; Day, Simon; Mahableshwarkar, Atul; Kempf, Lucas; Sheean, Maria; Dunn, Judith

Busner, Joan; Pandina, Gahan; Day, Simon; Mahableshwarkar, Atul; Kempf, Lucas; Sheean, Maria; Dunn, Judith.

Affiliation

Busner J; Dr. Busner is with Signant Health in Blue Bell, Pennsylvania and Department of Psychiatry, Virginia Commonwealth University School of Medicine in Richmond, Virginia.
Pandina G; Dr. Pandina is with Janssen Pharmaceuticals in Titusville, New Jersey.
Day S; Dr. Day is with Clinical Trials Consulting and Training, Ltd. in North Marston, England, United Kingdom. At the time of this writing.
Mahableshwarkar A; Dr. Mahableshwarkar was with Emalex Biosciences; he is now with ARM Pharma Consulting in Deerfield, Illinois.
Kempf L; Dr. Kempf is with Parexel in Washington, DC.
Sheean M; Dr. Sheean is with the European Medicines Agency in Amsterdam, North Holland, Netherlands.
Dunn J; Dr. Dunn is with Fulcrum Therapeutics in Cambridge, Massachusetts.

Innov Clin Neurosci ; 20(1-3): 25-31, 2023.

Article in En | MEDLINE | ID: mdl-37122576

Key words

CNS orphan drug development; CNS pediatric drug development; CNS rare disease drug development; Patient centricity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Innov Clin Neurosci Year: 2023 Document type: Article Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google